GlassScriptPhysician profile
Lauren M Bleich
NPI 1083882989
$12,801.56
in general payments reported to CMS, 2019-2025
38 companies · $3,110 in 2025
The $3,110 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,398 · 2020: $371 · 2021: $138 · 2022: $1,249 · 2023: $2,913 · 2024: $3,623 · 2025: $3,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,617 · Education: $28.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,616.84 |
| Education | $28.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,763.15 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,689.54 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,453.23 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,072.27 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $807.48 | 2019-2025 | |
| Gilead Sciences, INC. | $742.34 | 2019-2025 | |
| Celgene Corporation | $615.67 | 2021-2024 | Zeposia |
| Genzyme Corporation | $589.98 | 2022-2025 | |
| Boston Scientific Corporation | $493.19 | 2022-2024 | Captivator II, X-Tack Endoscopic Helix Tacking System, Exalt Model D |
| Regeneron Healthcare Solutions, INC. | $356.45 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $313.92 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $270.91 | 2024 | Tremfya, Stelara |
| Qol Medical, LLC | $268.78 | 2023-2025 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $185.74 | 2019-2025 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $159.68 | 2024-2025 | Iqirvo |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Bleich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.